Table 1.
Baseline Patient Characteristics
| Characteristic | No. (%) |
|---|---|
|
| |
| Total No. Patients | 56 |
|
| |
| Median age, y (range) | 68 (42–83) |
| Age < 60 | 12 (21) |
| Age ≥ 60 | 44 (79) |
|
| |
| Sex | |
| Male | 40 (71) |
| Female | 16 (29) |
|
| |
| Performance Status | |
| 0 | 25 (45) |
| 1 | 28 (50) |
| 2 | 2 (3) |
| Not available | 1 (2) |
|
| |
| Diagnosis | |
| AML | 28 (50) |
| MDS | 12 (21) |
| CMML | 4 (7) |
| t-MN | 11 (20) |
| PMF | 1 (2) |
|
| |
| Stage of Disease | |
| Previously untreated | 16 (29) |
| Primary refractory | 22 (39) |
| Relapsed/refractory | 18 (32) |
|
| |
| Median no. Prior Therapies (range) | 1 (0–7) |
|
| |
| Prior Therapies | |
| Untreated | 16 (29) |
| Cytarabine based | 23 (41) |
| Hypomethylating agent | 14 (25) |
| Allogeneic stem cell transplant | 9 (16) |
| Autologous stem cell transplant | 1 (2) |
|
| |
| Karyotypic Risk Group | |
| ∞ Favorable | 11 (20) |
| Intermediate | 19 (34) |
| Unfavorable | 23 (41) |
| Not available | 3 (5) |
t-MN= therapy related myeloid neoplasm, PMF= primary myelofibrosis.
∞
denotes 11 patients with MDS or CMML with good risk cytogenetics including 3 with a del 20q clone, 2 with del 5q clone and 6 with normal karyotype.